×
Volver a Agendas
Session Chair(s)
Ryuta Nakamura, PhD
Review Director, Office of New Drug II
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Speaker(s)
Recent Review Experiences of MRCT Data and a Direction of ICH E17 Guideline
Shuji Kamada
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Reviewer, Office of New Drug V
Future Drug Development and Impacts of ICH E17 Guideline: JPMA Perspective
Osamu Komiyama
Pfizer R&D Japan G.K., Japan
Senior Manager, Statistical Research & Data Science
Future Drug Development Strategies and Impact of ICH E17 Guideline: Pharmaceutical Company Perspective
Laurie Letvak, MD
Novartis Pharmaceuticals Corporation, United States
Head Clinical Policy and Medical Ethics
¿Tiene una cuenta?